Departments of1Neurological Surgery and.
3Center for Image-Guided Neurosurgery, and.
J Neurosurg. 2018 Jan;128(1):14-22. doi: 10.3171/2016.9.JNS161011. Epub 2017 Jan 20.
OBJECTIVE The goal of this study was to use 4 prognostic indices to compare survival times of patients who underwent Gamma Knife stereotactic radiosurgery (SRS) to treat melanoma brain metastases. METHODS The authors analyzed 422 consecutive patients (1440 brain metastases) who underwent Gamma Knife SRS. The median total brain tumor volume was 4.7 cm (range 0.3-69.3 cm), and the median number of metastases was 2 (range 1-32). One hundred thirty-two patients underwent whole-brain radiation therapy. Survival times were compared using recursive partitioning analysis (RPA), the Score Index for Radiosurgery (SIR), the Basic Score for Brain Metastases (BSBM), and the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA). RESULTS The overall survival times after SRS were compared. With the RPA index, survival times were 2.6 months (Class III, n = 27), 5.5 months (Class II, n = 348), and 13.0 months (Class I, n = 47). With the DS-GPA index, survival times were 2.8 months (Scores 0-1, n = 67), 4.2 months (Scores 1.5-2.0, n = 143), 6.6 months (Scores 2.5-3.0, n = 111), and 9.4 months (Scores 3.5-4.0, n = 101). With the SIR, survival times were 3.2 months (Scores 0-3, n = 56), 5.8 months (Scores 4-7, n = 319), and 12.7 months (Scores 8-10, n = 47). With the BSBM index, survival times were 2.6 months (BSBM0, n = 47), 5.4 months (BSBM1, n = 282), 11.0 months (BSBM2, n = 86), and 8.8 months (BSBM3, n = 7). The DS-GPA index was the most balanced by case numbers in each class and provided the overall best prognostic index for overall survival. CONCLUSIONS The DS-GPA index proved most balanced and predictive of survival for patients with melanoma who underwent SRS as part of management for brain metastases. Patients whose DS-GPA score was ≥ 2.5 had predictably improved survival times after SRS.
本研究旨在使用 4 种预后指标比较行伽玛刀立体定向放射外科(SRS)治疗黑素瘤脑转移患者的生存时间。
作者分析了 422 例连续接受伽玛刀 SRS 治疗的患者(1440 个脑转移灶)。中位全脑肿瘤体积为 4.7cm(范围 0.3-69.3cm),中位转移灶数为 2 个(范围 1-32 个)。132 例患者接受了全脑放疗。采用递归分区分析(RPA)、评分指数放疗(SIR)、脑转移基本评分(BSBM)和诊断特异分级预后评估(DS-GPA)比较生存时间。
比较了 SRS 后的总生存时间。根据 RPA 指数,生存时间为 2.6 个月(III 级,n=27)、5.5 个月(II 级,n=348)和 13.0 个月(I 级,n=47)。根据 DS-GPA 指数,生存时间为 2.8 个月(评分 0-1,n=67)、4.2 个月(评分 1.5-2.0,n=143)、6.6 个月(评分 2.5-3.0,n=111)和 9.4 个月(评分 3.5-4.0,n=101)。根据 SIR,生存时间为 3.2 个月(评分 0-3,n=56)、5.8 个月(评分 4-7,n=319)和 12.7 个月(评分 8-10,n=47)。根据 BSBM 指数,生存时间为 2.6 个月(BSBM0,n=47)、5.4 个月(BSBM1,n=282)、11.0 个月(BSBM2,n=86)和 8.8 个月(BSBM3,n=7)。DS-GPA 指数在每个类别中的病例数分布最均衡,提供了总体最佳的生存预后指数。
DS-GPA 指数对接受 SRS 治疗的黑素瘤脑转移患者的生存预测最为均衡。DS-GPA 评分≥2.5 的患者 SRS 后生存时间可预测性提高。